ITM_Logo_Claim_RGB_high-res.png
ITM Multiplies Production Capacity for its n.c.a. Lutetium-177
October 13, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the successful completion of a new production...
ITM_Logo_Claim_RGB_high-res.png
ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network
September 08, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, Germany, and Grand Rapids, MI, U.S., September 08, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and BAMF (Bold Advanced Medical...
ITM_Logo_Claim_RGB_high-res.png
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
September 06, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...
ITM_Logo_Claim_RGB_high-res.png
ITM Acquires a New Platform for the Development of Next-Generation Theranostics
August 18, 2022 05:18 ET | ITM Isotope Technologies Munich SE
• Technology platform for PET tracers strengthens ITM’s radiodiagnostic portfolio • Additional assets potentially expand ITM’s pipeline of novel targeted radionuclide therapeutics Garching /...
ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board
July 22, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, July 22, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board...
ITM_Logo_Claim_RGB_high-res.png
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
June 21, 2022 11:45 ET | ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...
ITM_Logo_Claim_RGB_high-res.png
ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress
June 15, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, June 15, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host an industry-sponsored lunch symposium on...